EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling of HCAR1 signalling reveals Gα i/o and Gα s activation without β‐arrestin recruitment and the discovery of an allosteric agonist

Simon Lind, Shane C Wright, Emilia Gvozdenovic, Kristina Nilsson, Kenneth L Granberg, Michel Bouvier iD, Linda C Johansson iD

British Journal of Pharmacology · 2026-05 · 183 (10) · 2219-2235

DOI: 10.1111/bph.70312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 23.12.2025. Verfasst von Simon Lind und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry and Cell biology, Gothenburg University, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, beta-Arrestins, GTP-Binding Protein alpha Subunits, Gi-Go. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada, Stiftelsen Konung Gustaf V:s 80-årsfond, Ragnar Söderbergs stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues. HCAR1 activation has been shown to regulate lipolysis and improve insulin sensitivity, positioning it as a promising therapeutic target for metabolic disorders such as obesity and type 2 diabetes. Despite its potential, its role in cancer progression and the limited availability of characterized ligands necessitate further investigation into its signalling mechanisms. This study aimed to broaden the pharmacological understanding of HCAR1 by investigating previously uncharacterized ligands and profiling their signalling properties. Experimental Approach We employed enhanced bystander bioluminescence resonance energy transfer (ebBRET) assays to investigate G protein activation and β‐arrestin recruitment following ligand stimulation of HCAR1. A panel of compounds was screened to identify more potent agonists and modulators of HCAR1 signalling. Key Results We identified AZ7136 as a relatively potent HCAR1 agonist, AZ2114 as a partial agonist, and GPR81 agonist 1 as an ago‐positive allosteric modulator. HCAR1 preferentially activated Gα i/o and Gα s pathways without recruiting β‐arrestins, revealing a distinct signalling profile. Conclusion and Implications These findings expand our understanding of HCAR1 signalling and introduce new molecular tools for probing its physiological and pathological roles. The characterized ligands may support future therapeutic strategies targeting HCAR1 in metabolic disorders while informing approaches to mitigate potential oncogenic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-Coupledbeta-ArrestinsGTP-Binding Protein alpha Subunits, Gi-GoHumansSignal TransductionAllosteric RegulationHEK293 CellsAnimalsLigands

Stichwörter der Autor:innen

G‐protein‐coupledallosteric modulationdrug screening assaymetabolismreceptorssignal transduction

Substanzen

Receptors, G-Protein-Coupledbeta-ArrestinsHCAR1 protein, humanGTP-Binding Protein alpha Subunits, Gi-GoLigands

Autor:innen und Institutionen

  • Department of Medical Biochemistry and Cell biology, Gothenburg University, Gothenburg, Sweden.
  • Department of Physiology & Pharmacology, Section for Personalized Medicine and Drug Development, Karolinska Institutet, Stockholm, Sweden.
  • Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
  • Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
  • Department of Biochemistry and Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.

ORCID-Profile: Michel Bouvier, Linda C Johansson

Förderung

  • Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
  • Stiftelsen Konung Gustaf V:s 80-årsfond
  • Ragnar Söderbergs stiftelse
  • Stiftelsen för Strategisk Forskning
  • Svenska Sällskapet för Medicinsk Forskning
  • Knut och Alice Wallenbergs Stiftelse
  • Jeanssons Stiftelser
  • Institute of Circulatory and Respiratory Health

Zitieren

APA

Lind, S., Wright, S. C., Gvozdenovic, E., Nilsson, K., Granberg, K. L., Bouvier, M., & Johansson, L. C. (2026). Profiling of HCAR1 signalling reveals Gα i/o and Gα s activation without β‐arrestin recruitment and the discovery of an allosteric agonist. British Journal of Pharmacology, 183(10), 2219-2235. https://doi.org/10.1111/bph.70312

Vancouver

Lind S, Wright SC, Gvozdenovic E, Nilsson K, Granberg KL, Bouvier M, et al. Profiling of HCAR1 signalling reveals Gα i/o and Gα s activation without β‐arrestin recruitment and the discovery of an allosteric agonist. British Journal of Pharmacology. 2026;183(10):2219-2235. doi:10.1111/bph.70312

BibTeX
@article{Lind2026,
  author = {Lind, Simon and Wright, Shane C and Gvozdenovic, Emilia and Nilsson, Kristina and Granberg, Kenneth L and Bouvier, Michel and Johansson, Linda C},
  title = {Profiling of HCAR1 signalling reveals Gα i/o and Gα s activation without β‐arrestin recruitment and the discovery of an allosteric agonist},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {10},
  pages = {2219--2235},
  doi = {10.1111/bph.70312}
}
Kostenlos starten →